139 INTRAVENOUS CONTINUOUS HOME INOTROPIC THERAPY IN ADVANCED HEART FAILURE - RESULTS AND PRACTICAL GUIDELINES. (15th December 2022)

• Record Type: Journal Article
• Authors: Gentile, Piero; Palazzini, Matteo; Tedeschi, Andrea; Ammirati, Enrico; Perna, Enrico; Verde, Alessandro; D´angelo, Luciana; Masciocco, Gabriella; Garascia, Andrea
• Is Part Of: European heart journal supplements. Volume 24(2022)Supplement K
• Publication Date: 2022-12-15
• Subjects: Cardiology -- Periodicals; Cardiology -- Europe -- Periodicals; 616.12005
• DOI: 10.1093/eurheartjsupp/suac121.474
• Languages: English
• ISSNs: 1520-765X

Abstract

Abstract: Background: no firm data exist regarding continuous intravenous inotropic infusion in outpatients with advanced heart failure (AHF). Methods: We reviewed medical records of all inotrope dependent patients discharged from our institution on continuous home inotropes infusion for AHF after a hospitalization between 2014 and 2021. Indications for inotropic agents included bridge to transplant (BTT) or to candidacy (BTC) strategies or palliative care. We compared the number of hospitalizations the year before and the year after beginning the inotrope continuous infusion, assessing the main hospital diagnosis and the duration of hospital recovery in days, through hospital charts revision. Moreover, we used a linkert 7 item scale to assess quality of life (QoL) and, using peripheral blood sample, we esteemed the end organ damage trend evaluating NTproBNP, creatinine, blood urea nitrogen (BUN) and bilirubin. Results: From 2014 to 2021, 27 patients (Median age 56 years (Q1-Q3 50-63 years), 74% male and 26% female) were dismissed with continuous inotrope infusion from our institution. The total number of days of hospital stay was 1591 the year before beginning inotropic support (average 58.93 ± 38.70 for patient), significantly different if compared with the post inotropes period (average 22, 19 ± 36, 84 days for patients, IC 95% 17, 488-55, 994 p < 0, 001). Moreover, the number of hospitalizations per patient fell from 1.93 ± 0.997 to 0, 93 ± 0, 958 (IC 95% 0, 522- 1, 478, p < 0, 001). After 6 months, 53% of the patients experienced an improvement in quality of life. Regarding end organ damage, while creatinine and BUN showed a significant reduction in the first month, with a trend to stability in the following period, bilirubin and NTproBNP significantly trended to reduction during the 6 month of monitoring. Conclusions: In a real world population of contemporary AHF, continuous inotropes home infusion documented an improvement in hospitalization, QoL and end organ damage. We offer a practical guideline on initiation, selection and maintenance of chronic inotrope therapy in a population of challenging patients.